Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.

Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

President-elect Donald Trump wants to acquire Greenland. This is not merely one of his japes, as it may have been during his ...

Ozempic, Wegovy and Mounjaro featured prominently. Known for their use in managing type 2 diabetes and aiding weight loss for ...

Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...